Cover Image
Market Research Report

Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 823167
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
Published: March 29, 2019 Content info: 120 Pages
Description

About this market

The increasing prevalence of STDs is one of the key factors expected to trigger the market's growth in the forthcoming years. STDs are rising in the emerging and advanced economies, resulting in the rising demand for drugs and therapies for treating these chronic illnesses. The cases of these incidences has increased considerably in the recent years owing to the transmission of different bacteria, viruses, and parasites during sexual contact. As a result, the increasing prevalence of STDs will further propel the demand for drugs and therapies, in turn, contributing significantly to the STD treatment market growth during the forecast period. Technavio's analysts have predicted that the sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.

Market Overview

Approval of drugs and a strong pipeline

One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.

Social stigma associated with STDs

One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31124

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Viral infections - Market size and forecast 2018-2023
  • Bacterial infections - Market size and forecast 2018-2023
  • Other infections - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Viral infections - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Viral infections - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Bacterial infections - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Bacterial infections - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Other infections - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Other infections - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Pipeline drugs for STDs
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Some of the HIV vaccines under clinical trials
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 48: Bristol-Myers Squibb Company - Business segments
  • Exhibit 49: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 50: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 51: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 52: Gilead Sciences, Inc. - Vendor overview
  • Exhibit 53: Gilead Sciences, Inc. - Business segments
  • Exhibit 54: Gilead Sciences, Inc. - Organizational developments
  • Exhibit 55: Gilead Sciences, Inc. - Geographic focus
  • Exhibit 56: Gilead Sciences, Inc. - Key offerings
  • Exhibit 57: GlaxoSmithKline plc - Vendor overview
  • Exhibit 58: GlaxoSmithKline plc - Business segments
  • Exhibit 59: GlaxoSmithKline plc - Organizational developments
  • Exhibit 60: GlaxoSmithKline plc - Geographic focus
  • Exhibit 61: GlaxoSmithKline plc - Segment focus
  • Exhibit 62: GlaxoSmithKline plc - Key offerings
  • Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 69: Merck & Co., Inc. - Vendor overview
  • Exhibit 70: Merck & Co., Inc. - Business segments
  • Exhibit 71: Merck & Co., Inc. - Organizational developments
  • Exhibit 72: Merck & Co., Inc. - Geographic focus
  • Exhibit 73: Merck & Co., Inc. - Segment focus
  • Exhibit 74: Merck & Co., Inc. - Key offerings
  • Exhibit 75: Validation techniques employed for market sizing
Back to Top